Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., announced the publication of exploratory Phase 2 clinical trial results for its core product, Tiengogatinib, targeting cholangiocarcinoma in the journal "The Lancet Gastroenterology & Hepatology" [1] Group 1: Clinical Trial Details - The Phase 2 study (NCT04919642) is an open-label, multicenter trial involving eligible cholangiocarcinoma patients, including those with FGFR2 fusions and primary or acquired resistance to FGFR inhibitors [1] - Tiengogatinib demonstrates the ability to overcome acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma patients and shows antitumor activity in patients with other FGFR gene alterations [1] Group 2: Disease Background - Cholangiocarcinoma is a highly aggressive cancer of the biliary system, often driven by FGFR2 fusions, which can be targeted by inhibitors such as pemigatinib and futibatinib [1] - The emergence of acquired FGFR2 mutations frequently leads to resistance against these targeted therapies [1]

Core Viewpoint - The company, Zai Lab Limited, announced the publication of exploratory Phase 2 clinical trial results for its core product, Tzenglongtinib, targeting cholangiocarcinoma in a high-impact medical journal [1] Group 1: Clinical Trial Details - The Phase 2 study (NCT04919642) is an open-label, multicenter trial involving eligible cholangiocarcinoma patients with FGFR2 fusions and primary or acquired resistance to FGFR inhibitors [1] - The study also includes patients with other FGFR gene alterations and those with wild-type FGFR [1] Group 2: Drug Efficacy - Tzenglongtinib demonstrates the ability to overcome acquired resistance to FGFR inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma [1] - The drug shows anti-tumor activity in cholangiocarcinoma patients with other FGFR gene alterations [1]

Core Insights - The core product of the company, Tiengotine, has shown promising results in a Phase 2 exploratory clinical trial for cholangiocarcinoma published in The Lancet Gastroenterology & Hepatology [1] Company Summary - Tiengotine is designed to overcome acquired resistance to FGFR inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma, demonstrating anti-tumor activity in patients with other FGFR gene alterations and FGFR wild-type patients [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2617） 自願性公告 1 上市規則第18A.08(3)條規定的警示聲明：無法保證本公司將能最終成功開發及銷 售相關產品。 承董事會命 發表核心產品替恩戈替尼針對膽管癌的探索性臨床結果 本公告由藥捷安康（南京）科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以向本公司股東及潛在投資者提供有關本集團的最新業務進 展。 本公司董事會（「董事會」）欣然宣佈，近日，本公司核心產品替恩戈替尼在美國開 展的針對膽管癌的探索性臨床2期結果在《柳葉刀，胃腸病和肝病學》（影響因子 38.6）上發表。 膽管癌是一種侵襲性極強的膽道系統癌症，其發病常由FGFR2融合驅動，這類突 變可通過佩米替尼(pemigatinib)和福替巴替尼(futi ...

Core Viewpoint - The Hong Kong stock market has shown significant gains, with several companies experiencing substantial increases in their stock prices, indicating a positive market sentiment and potential investment opportunities. Group 1: Stock Performance - Times China Holdings (01233.HK) has seen a remarkable increase of 42.99% [1][2] - Shin-Etsu Holdings (06038.HK) has risen by 36.96% [1][2] - QPL International (00243.HK) has gained 24.62% [1][2] - ZhiHua Group (01842.HK) has increased by 24.39% [1][2] - Gaoke Bridge (09963.HK) has risen by 19.19% [1][2] - Tianli Holdings Group (00117.HK) has seen an increase of 18.75% [1][2] - Simple Life (08360.HK) has gained 16.67% [1][2] - Yaojie Ankang-B (02617.HK) has increased by 16.18% [1][2] - Yangtze Optical Fibre and Cable (06869.HK) has risen by 14.07% [1][2] - Jingsui Holdings (01862.HK) has seen an increase of 13.33% [1][2]

Group 1 - The Hang Seng Index rose by 0.22%, gaining 55 points to reach 25,291 points, while the Hang Seng Tech Index increased by 0.02% with a trading volume of 84.8 billion HKD in the morning session [1] - Yichun City announced the cancellation of 27 mining rights, leading to a surge in lithium stocks, with Ganfeng Lithium rising over 6% and Tianqi Lithium increasing by over 5% [1] - Airlines showed strong performance in November's off-peak season, with Southern Airlines up over 7%, Eastern Airlines up over 5%, and Air China rising by 5% [1] Group 2 - Jiangxi International Resources saw a 6% increase as tungsten prices accelerated, reaching a historical high for tungsten concentrate [1] - Junda Co., Ltd. rose over 6% after its Chuzhou base achieved large-scale production of TOPCon batteries [1] - Changfei Optical Fiber and Cable increased by nearly 11% driven by AI computing power demand [2] Group 3 - Yaojie Ankang-B surged by 18% after announcing positive clinical results for Tiengatin in a sub-journal of The Lancet [3] - Li Ning rose by 4% with the launch of new Dragon Store and Honor Gold Standard product series, expected to create strong synergy [4] - Zhongjiao Holdings increased by 6% as its adjusted annual EBITDA exceeded expectations, with institutions focusing on subsequent classification registration progress [5] Group 4 - Tanwan rose over 4%, accumulating over 30% growth this month, partnering with COEXIST to expand its trendy toy industry layout [6] - Zhaoyan Pharmaceutical increased by over 10% as the price of experimental monkeys rose, with institutions expecting a tight supply-demand situation to persist [7] - Yidu International fell over 12% in the morning session, giving back most of its gains for the month, as Muxi Co., Ltd. listed on the Sci-Tech Innovation Board today [8]

Group 1 - The stock of药捷安康-B (02617.HK) surged nearly 14%, reaching a price of 166.1 HKD, with a trading volume of 112 million HKD [1]

Core Viewpoint - The stock of Jiangsu Hengrui Medicine Co., Ltd. (02617) surged nearly 14% following the announcement of positive clinical results for its core product, Tiengogatinib, published in a prestigious medical journal [1] Group 1: Clinical Results - Tiengogatinib demonstrated durable responses and extended survival in patients with cholangiocarcinoma during a Phase 2 exploratory clinical trial conducted in the United States [1] - The study results were published in "The Lancet Gastroenterology & Hepatology," which has an impact factor of 38.6 [1] - Researchers from the University of Texas MD Anderson Cancer Center highlighted the need for next-generation FGFR2 inhibitors, with Tiengogatinib being noted for its unique mechanism targeting FGFR [1] Group 2: Product Information - Tiengogatinib is an innovative multi-target small molecule kinase inhibitor developed independently by the company, currently in the registration clinical phase [1] - The drug targets tumor cells and improves the tumor microenvironment to exert anti-tumor effects [1] - Tiengogatinib has received orphan drug designation (ODD) and fast track designation from the FDA for cholangiocarcinoma treatment, and it is included in the breakthrough therapy list and priority review list by China's NMPA [1]

Core Viewpoint - The stock of Jiangsu Hengrui Medicine Co., Ltd. (02617) surged nearly 14%, reaching HKD 166.1 with a trading volume of HKD 112 million, following the announcement of positive exploratory Phase II clinical trial results for its core product, Tiengogatin, in treating cholangiocarcinoma published in a high-impact journal [1] Group 1: Clinical Trial Results - Tiengogatin, a next-generation FGFR2 inhibitor, demonstrated durable responses and prolonged survival in cholangiocarcinoma patients during the Phase II study, prompting researchers to support the initiation of a Phase III registration trial [1] - The study was commented on by researchers from the MD Anderson Cancer Center, highlighting the search for next-generation FGFR2 inhibitors [1] Group 2: Product Development and Regulatory Status - Tiengogatin is an innovative multi-target small molecule kinase inhibitor developed in-house, targeting tumor cells and improving the tumor microenvironment for anti-tumor effects [1] - The product has received orphan drug designation (ODD) and fast track designation from the FDA for cholangiocarcinoma, and has been included in the breakthrough therapy and priority review lists by China's NMPA, as well as receiving ODD from the European EMA for cholangiocarcinoma treatment [1]

每经AI快讯，12月9日，港股药捷安康-B尾盘一度跳水，跌超10%。 ...